86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 35-36

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

Background

After first-line endocrine therapy (ET) plus CDK4/6 inhibitor (CDK4/6i) in estrogen receptor–positive/HER2-negative (ER+/HER2–) metastatic breast cancer, tumors eventually develop resistance. In the phase 3 EMERALD trial (NCT03778931), elacestrant significantly improved progression-free survival (PFS) vs standard-of-care (SOC) ET (ESR1-mutated tumors HR, 0.55; 95% CI, 0.39-0.77; P= .0005; all patients HR, 0.70; 95% CI, 0.55-0.88; P = .0018) with a manageable safety profile in patients with ER+/HER2– metastatic breast cancer previously treated with ET plus CDK4/6i. To address various resistance mechanisms, the phase 1/2 ELEVATE trial (NCT05563220) evaluates elacestrant with everolimus, alpelisib, capivasertib, ribociclib, palbociclib, or abemaciclib.

Materials and Methods

Eligible patients have ER+/HER2– metastatic breast cancer, 1 to 2 lines of prior ET. The phase 1b objective is to identify the recommended phase 2 dose (RP2D) of each combination. The phase 1/2 ELECTRA (NCT05386108) evaluated the RP2D of elacestrant plus abemaciclib. The phase 2 objective is to evaluate PFS with each combination at the RP2D. This analysis reports updated RP2D safety for abemaciclib, everolimus, and palbociclib combinations and phase 1b safety for the other combinations.

Results

As of October 15, 2024, most common treatment-emergent adverse events (TEAEs) 15% or more for the following RP2D combinations are reported: elacestrant at 345 mg plus abemaciclib at 150 mg twice daily (n = 30): diarrhea (80%; 7% grade 3/4), nausea (63%; 7% grade 3/4), fatigue (43%, 7% grade 3/4), vomiting (43%; 0 grade 3/4), constipation (30%; 0 grade 3/4), median PFS was not reached, median observation time was 4.6 months at data cut-off; elacestrant at 345 mg plus everolimus at 7.5 mg (n = 57): nausea (51%; 2% grade 3/4), diarrhea (40%; 5% grade 3/4), stomatitis (33%; 4% grade 3/4), median PFS was not reached, median observation time was 2.8 months at data cut-off; elacestrant at 345 mg plus palbociclib plus 125 mg (n = 7): neutropenia (57%; 43% grade 3/4, mostly related to palbociclib). Most common TEAEs (≥35%) in the ongoing phase 1b combinations at the current test doses are reported:elacestrant at 172 mg plus ribociclib at 600 mg (n = 6): neutropenia (50%; 33% grade 3/4, mostly related to ribociclib), nausea, vomiting, fatigue (each 50%, 0 grade 3/4); elacestrant at 258 mg plus capivasertib at 320 mg (n = 7): fatigue, nausea (57% each, 0 grade 3/4), vomiting, diarrhea (43% each, 0 grade 3/4); elacestrant at 258 mg plus alpelisib at 200 mg (n = 6): nausea (83%; 0 grade 3/4), rash, hyperglycemia (50% each; 17% grade 3/4), stomatitis, blurred vision, dizziness (each 50%; 0 grade 3/4).

Conclusion

The evaluated combinations continue to demonstrate a known safety profile consistent with each drug plus SOC ET and no increased risk of associated AEs. Elacestrant has the potential to become the ET partner for multiple targeted agents, providing an all-oral treatment option in patients with ER+/HER2– metastatic breast cancer, delaying chemotherapy or antibody-drug conjugate–based regimens.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Related Content